Novel Antiplatelet May Boost Coronary Artery Bypass Graft Survival, Uppsala University Hospital Study

Published: Dec 30, 2010

MedPageToday -- The novel reversible antiplatelet agent ticagrelor (Brilinta) was associated with lower mortality from coronary artery bypass graft surgery (CABG) compared with standard clopidogrel (Plavix), according to a subanalysis of the pivotal PLATO trial.

Back to news